Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1052W HIGH $5.95
Volume
16.86 K
Value Traded
744.26 K
Short % Float
7.54%
-5.76%Week
+3.58%1 Month
+3,368.63%3 Month
+1,988.89%6 Month
-98.39%5 Year
-98.39%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.05 M
EPS (TTM)
-9.57
P/E Ratio
-
Ent. Value
3.48 M
Total Shares
1.34 M
Float Shares
780.00 K
Insiders
41.73%
Institutions
1.41%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LIMN Catalyst Timeline
Dated clinical, regulatory and corporate events for Liminatus Pharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Liminatus Pharma, Inc.
14Total events
2Upcoming
3Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T3Enrollment Update
Subscribe to view catalyst details
Event history 10
▲Other Regulator MilestoneEx-US Regulatory
Liminatus regained compliance with Nasdaq minimum bid price rule
▲Other Regulator MilestoneIBC101Ex-US Regulatory
MFDS authorization received for IBC101 Phase 1/2a study
relapsed or refractory diffuse large B-cell lymphoma (DLBCL)source ↗
●Other Regulator MilestoneEx-US Regulatory
Nasdaq Hearings Panel transferred Liminatus to The Nasdaq Capital Market
◆AcquisitionCorporate
Amended merger agreement with InnocsAI to expand oncology cell therapy pipeline
oncologysource ↗
◆AcquisitionCorporate
Liminatus Pharma amends merger agreement with InnocsAI to expand oncology cell therapy pipeline
oncologysource ↗
▼Other Regulator MilestoneEx-US Regulatory
Liminatus received Nasdaq notice of non-compliance with minimum bid price rule
Past FDA Catalysts and PDUFA Decisions
How LIMN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every LIMN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Valetudo Therapeutics LLC10% Owner | Other | 3,448,926 5,244,351 held | $0.00 | 07/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LIMN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LIMN for Q2 2026. | ||||
LIMN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LIMN ranks across every disease it competes in
Competitive Position is a premium feature
See how LIMN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLIMN News
LIMN▼ -8.4%on this news
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
Liminatus Pharma, Inc. has successfully regained compliance with Nasdaq's minimum bid price rule after its stock price exceeded $1.00 for 13 consecutive trading days. This follows a previous notice from Nasdaq regarding non-compliance due to a prolonged low stock price. The company had undergone a reverse stock split to facilitate this compliance.
Read more →LIMN▼ -9.5%on this news
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
Liminatus Pharma has partnered with Synex Consulting to advance its CD19xCD22 bivalent CAR-T therapy, IBC101, into clinical trials in South Korea. The therapy has received authorization for a Phase 1/2a study targeting relapsed or refractory diffuse large B-cell lymphoma. This collaboration aims to leverage Synex's expertise in clinical development to facilitate patient enrollment and overall progress of the trial.
Read more →LIMN▼ -14.1%on this news· ran to -28% by day 3shared move
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
Liminatus Pharma, Inc. announced a 1-for-50 reverse stock split approved by stockholders. This split will take effect on August 20, 2026, with shares trading on a split-adjusted basis starting August 21, 2026. The move aims to enhance the company's stock value while maintaining stockholders' proportional ownership.
Read more →LIMN▲ +38.2%on this newsshared move
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
Liminatus Pharma has successfully transferred its stock listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026. The Nasdaq Hearings Panel has granted the company additional time until September 3, 2026, to comply with the minimum bid price requirement. The company is committed to taking necessary actions to regain compliance while continuing its clinical development efforts.
Read more →LIMNLiminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
Liminatus Pharma has amended its merger agreement with InnocsAI to expedite the closing process, now expected on July 2, 2026. The deal includes a mix of common stock and non-voting convertible preferred stock, valued at approximately $320 million. This merger aims to enhance Liminatus' oncology pipeline and create strategic partnerships in cancer therapy.
Read more →LIMN▼ -22.2%on this news
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
Liminatus Pharma has entered into a warrant exercise agreement, raising $1.9 million from existing investors. The agreement involves the exercise of 10,344,000 shares of common stock and the issuance of new warrants for 20,688,000 shares. The new warrants have an exercise price of $0.18 and require stockholder approval before they can be exercised.
Read more →LIMN▼ -31.1%on this news
Liminatus Pharma Announces Nasdaq Delisting Notification
Liminatus Pharma has received a delisting notification from Nasdaq due to failure to meet market value requirements. The company was given a grace period to regain compliance but did not succeed. Unless an appeal is filed by May 27, 2026, trading of its securities will be suspended on May 29, 2026. The company intends to appeal the decision.
Read more →LIMN▲ +31%on this newsshared move
Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline
Liminatus Pharma has announced a merger with InnocsAI to enhance its oncology cell therapy pipeline. The merger will involve the acquisition of multiple biologic and cellular therapy assets aimed at addressing challenges in hematologic cancers and solid tumors. The transaction is valued at approximately $320 million and is expected to provide development opportunities across various cancer indications.
Read more →LIMN▼ -31.9%on this news
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
Liminatus Pharma, Inc. announced the pricing of a public offering of 13,813,000 shares at $0.29 each, aiming to raise $4.0 million. The offering includes warrants for additional shares, potentially raising $6.0 million. The funds will support working capital and business objectives. The closing is expected on February 18, 2026.
Read more →LIMNLiminatus Pharma Announces Receipt of Nasdaq Listing Delinquency Letter
Liminatus Pharma has announced that it received a Nasdaq Listing Delinquency Letter due to a delay in filing its Quarterly Report on Form 10-Q. The letter does not immediately affect its stock listing as it retains its trading status on Nasdaq. The company is required to submit a plan for regaining compliance within 60 days, with a potential extension available if approved. This compliance challenge occurs as the company seeks to advance its immunotherapy drug, IBA101, targeting cancer. Investors should be aware of the uncertainties that may impact the company's future compliance with Nasdaq regulations.
Read more →LIMN▼ -6.4%on this news
IBA101: The Strategic Answer to the PD-1/L1 Patent Cliff
Liminatus Pharma, Inc. is addressing the impending patent expirations of PD-1/PD-L1 inhibitors with its next-generation CD47 monoclonal antibody, IBA101. The company believes IBA101 could synergize effectively with current therapies, enhancing their effectiveness while offering a favorable safety profile. As major players face the entry of biosimilars, Liminatus highlights the strategic value of its unique approach and established safety in the rapidly evolving immuno-oncology market. The success of IBA101 could alter the competitive dynamics by prolonging the lifecycle of existing PD-1/PD-L1 franchises.
Read more →LIMN▲ +33.4%on this news· ran to -53% by day 3
Liminatus Pharma Charts Dual-Front Attack on Next-generation CD47 inhibitor advances toward human trials in U.S. and Korea, with the prospect of safer, more potent immunotherapy
Liminatus Pharma is advancing its next-generation CD47 inhibitor, IBA101, towards human trials in the U.S. and Korea. With a focus on eliminating side effects seen in earlier CD47 candidates, IBA101 is designed to target tumor cells while sparing red blood cells and platelets. The company is preparing to submit its investigational new drug applications and has partnered with a lung cancer specialist for enhanced patient access and research capabilities. Liminatus expects the trials to start by 2027, aiming to reshape immunotherapy approaches in cancer treatment.
Read more →LIMN▲ +33.4%on this news· ran to -53% by day 3
Crafting the Future of Healing for Patients Next Generation CD47 Blockade with Liminatus Pharma, Innobation Bio Disclaimer This presentation (this "Presentation") has been assembled by Liminatus Pharma Limited, including
Liminatus Pharma is advancing its next-generation CD47 blockade therapy, IBA101, aimed at improving cancer treatment outcomes. The company highlights its experienced leadership, preclinical successes, and strategic plans for partnerships with major pharmaceutical firms like AstraZeneca and Merck. Preparations for a Phase 1 clinical trial are underway, demonstrating clear milestones for growth. Risks associated with regulatory approvals and market conditions remain, but Liminatus retains a strong financial position and a clear roadmap for future developments.
Read more →LIMN▲ +139.8%on this news· ran to +391% by day 3
Liminatus Pharma Announces Compliance with Nasdaq
Liminatus Pharma, Inc. has announced its compliance with Nasdaq Listing Rule 5250(c)(1) after filing its Quarterly Report on Form 10-Q. The notice of compliance was received on June 3, 2025, following a previous notification letter indicating non-compliance due to a delayed filing. With this resolution, Liminatus aims to focus on its development of innovative cancer therapies, particularly its CD47 monoclonal antibody candidate, IBA101.
Read more →LIMN▼ -23.6%on this news
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholder of Iris Parent Holding Corp.: Opinion on the Consolidated Financial Statements We have audited the accompanying consolidat
Iris Parent Holding Corp. has received an audit opinion confirming that its consolidated financial statements fairly present its financial position. However, the report highlights significant concerns over the Company's ability to continue as a going concern due to a lack of substantive operations and sufficient cash reserves. As of December 31, 2024, the Company reported an accumulated deficit and substantial liabilities, raising doubts about its future viability. Management's plans regarding these financial uncertainties are noted but not detailed in the document.
Read more →About Liminatus Pharma, Inc.
Headquarters12611 HIDDENCREEK WAY, CERRITOS, CA, 90703
BIOPHARMAWATCH ELITE PLUS
Trade the next LIMN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime